Physician profile
Caroline Walker
NPI 1962821124
$9,367.11
in general payments reported to CMS, 2019-2025
36 companies · $2,581 in 2025
The $2,581 reported for 2025 was more than what 84% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $677 · 2020: $14.69 · 2021: $712 · 2022: $1,312 · 2023: $1,839 · 2024: $2,231 · 2025: $2,581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,604 · Education: $47.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,603.83 |
| Education | $47.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,378.21 | 2020-2025 | Linzess, Skyrizi, Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $918.10 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $763.50 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Boston Scientific Corporation | $677.20 | 2019 | |
| Madrigal Pharmaceuticals | $459.61 | 2024-2025 | Rezdiffra, Resmetirom |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $453.72 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Pfizer INC. | $398.11 | 2021-2025 | |
| Qol Medical, LLC | $379.22 | 2022-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $365.12 | 2022-2025 | Ibsrela |
| Celgene Corporation | $326.29 | 2021-2024 | Zeposia |
| Genzyme Corporation | $246.87 | 2022-2025 | |
| Lilly USA, LLC | $219.28 | 2023-2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $172.78 | 2022-2024 | Dupixent |
| Phathom Pharmaceuticals, INC. | $161.38 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $150.34 | 2021-2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $139.87 | 2024-2025 | Vegzelma, Zymfentra |
| Braintree Laboratories, INC. | $139.64 | 2021-2024 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $128.44 | 2024 | |
| Aimmune Therapeutics, INC. | $95.26 | 2024-2025 | Zenpep, Vowst |
| E.R. Squibb & Sons, L.L.C. | $91.44 | 2023-2024 | Zeposia |
| Daiichi Sankyo INC. | $83.36 | 2021-2022 | |
| Evoke Pharma, INC. | $83.23 | 2022-2024 | Gimoti |
| Ipsen Biopharmaceuticals, INC | $65.55 | 2025 | Iqirvo |
| Shield Therapeutics INC | $55.08 | 2024 | |
| Merck Sharp & Dohme LLC | $53.60 | 2021-2022 | |
| Medtronic, INC. | $52.89 | 2024 | Gi Genius |
| Vivus LLC | $44.77 | 2022-2025 | Qsymia |
| Intercept Pharmaceuticals, INC. | $44.52 | 2023-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $42.89 | 2022-2024 | Rebyota |
| Cook Medical LLC | $39.53 | 2024-2025 | Resonance |
| Enterra Medical, INC. | $34.47 | 2024-2025 | |
| Redhill Biopharma INC. | $30.23 | 2023 | Talicia, Movantik, Aemcolo |
| Novo Nordisk INC | $28.19 | 2025 | Wegovy |
| Fresenius Kabi USA, LLC | $22.43 | 2023 | Idacio |
| Capsovision, INC. | $21.99 | 2023 | Capsocam Plus |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$23,657.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.